Navigation Links
PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients
Date:10/24/2008

ned to alleviate the symptoms of the disease. These treatments include chest physical therapy to clear the thick mucus from the lungs, antibiotics to treat lung infections, and a mucus-thinning drug designed to reduce the number of lung infections and improve lung function. In addition, the majority of cystic fibrosis patients take pancreatic enzyme supplements to assist with food absorption in digestion. There is a significant unmet medical need for treatments that address the underlying cause of CF. More information regarding CF is available through the Cystic Fibrosis Foundation (http://www.cff.org).

About PTC124

PTC124 is an orally delivered, investigational new drug discovered by PTC Therapeutics. The drug is being developed for the treatment of nonsense mutation genetic disorders. Nonsense mutations are single-point alterations in the genetic code that prematurely stop the mRNA translation process, leading to production of truncated, non-functional proteins. PTC124 induces the cellular translation machinery to read through nonsense mutations in mRNA, inducing production of full-length, functional proteins. PTC124 has demonstrated proof of concept in Phase 2a clinical trials. Across all clinical studies to date, PTC124 has been generally well tolerated. PTC124 is currently in Phase 2b development with the goal of demonstrating that increasing functional protein levels in patients with nonsense mutation genetic disorders will safely provide clinical benefits.

PTC124 has been granted orphan drug status by the FDA and the European Commission for the treatment of cystic fibrosis and Duchenne muscular dystrophy due to nonsense mutations. The FDA has also granted PTC124 Subpart E designation for expedited development, evaluation, and marketing.

PTC has an exclusive collaboration with Genzyme Corporation to develop and commercialize PTC124 outside the United States and Canada. The development o
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
4. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
5. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
6. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
7. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
8. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
9. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
10. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
11. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sep. 03, 2015 ... the addition of the "Investigation Report on China ... Oxiracetam, a derivative of pyrrolidone, was first synthesized ... whose oral preparation and injection entered the Italian market ... fast after entering China , annual ...
(Date:9/2/2015)... About Balloon Kyphoplasty VCF ... more vertebral bodies, resulting in persistent and unbearable ... is a leading cause of VCF among elderly ... tumors, and traumatic injuries also cause VCF. Individuals ... rectify the condition. Both procedures are minimally invasive ...
(Date:9/2/2015)... LONDON , Sept. 2, 2015 ... Forecasts Summary Advanced dressings have steadily ... treatment of a variety of wound indications, such ... fluid management, infection control, and physical protection become ... a greater role in standard therapy. This ...
Breaking Medicine Technology:Investigation Report on China's Oxiracetam Market, 2010-2019 2Global Balloon Kyphoplasty Market 2015-2019 2Advanced Wound Dressings - SA Analysis and Market Forecasts 2
... Confirm Robust Efficacy of CIMZIA, BOSTON, Nov. ... new,Phase III data from the RAPID 1 and ... Annual Scientific Meeting (ACR), which show,CIMZIA(R) (certolizumab pegol), ... Factor), given with methotrexate, is significantly,more effective than ...
... Fla., Nov. 7 A new analysis,presented today ... Evaluation Of Rosuvastatin) showed CRESTOR(R) (rosuvastatin calcium) 40,mg ... in four,patient populations at varying levels of risk ... subjects defined by the Framingham risk,assessment tool as ...
Cached Medicine Technology:CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 2CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 3CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 4CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 5CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 6CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 7CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 8New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6
(Date:9/2/2015)... ... 2015 , ... Sara Bleich, Ph.D., associate professor of health ... an internationally recognized scholar on obesity prevention and control, has been selected for ... and 1996 graduate of Garrison Forest School, an all-girls’ independent school in Owings ...
(Date:9/2/2015)... ... 02, 2015 , ... The CRISPR-Cas9 system introduces double-strand DNA breaks ... nuclease with either a chimeric single guide RNA (sgRNA) or two short RNAs (a ... RNA (sgRNA or crRNA) to create a break in the target DNA that causes ...
(Date:9/2/2015)... ... September 02, 2015 , ... On ... Officers Association of America (MOAA) and Wounded Warrior Project® (WWP), will be ... Own,” expert panelists will lead interactive discussions on the responsibilities and commitments ...
(Date:9/2/2015)... ... ... According to an article published August 12 by International Business Times, a new ... with grand juries in cases meant to decide if a police officer used deadly or ... decisions in Ferguson and New York City that absolved police officers of charges in the ...
(Date:9/2/2015)... ... September 02, 2015 , ... Telehealth represents a growing trend ... to handle the telehealth services of more than 12 Blues plan clients. The ... Plans takes a look this growing trend, interviewing executives at Capital Blue Cross, whose ...
Breaking Medicine News(10 mins):Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3
... Today, Tuesday, January 27, 2009, 9:30 A.M.** Elected ... Community Based Health System for Embracing Courageous New Direction ... Accord Includes Free and Fair Union ... Conference to announce historic hospital accords. WHEN: Today, ...
... seize billions from state, construct prison health care centers ... lawsuit was filed this week to prevent a federal ... dollars from California,s treasury for the sole purpose of ... Safe Ventura County opposes the proposal to construct seven ...
... Fitness Industry Leader Champions Gupta,s Commitment to Enriching Quality ... 27 The American Council on Exercise (ACE), America,s ... fitness certification, education and training organizations in the world, ... Dr. Sanjay Gupta , chief medical correspondent for the ...
... (NYSE: SGP ) today reported that it ... study, a pivotal Phase III study in treatment-naive patients. ... III study in patients who failed prior treatment that ... enrolled its registration studies for boceprevir, its lead investigational ...
... (NYSE Alternext US: ILI) today announced that the Company has ... "Exchange") that outlines the Company,s strategy to regain compliance with ... Exchange to formally respond to the submitted plan within 45 ... able to continue its listing up to June 23, 2010 ...
... ANTHEM, Ariz., Jan. 27 Prime Companies, Inc. ... , The Company has begun receiving income ... , The web site is now accessible ... , , "These are major achievements and ...
Cached Medicine News:Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 2Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 3Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 4Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 5Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 6Health News:Ventura County Taxpayers' Group Files Suit to Stop State-of-the-Art Hospitals for Incarcerated Felons 2Health News:American Council on Exercise (ACE) Endorses Appointment of Dr. Sanjay Gupta as Surgeon General of the United States 2Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 2Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 3Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 4Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 5Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 6Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 7Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 8Health News:Interleukin Genetics' Submits Plan to Regain Compliance with Continued Listing Standards 2Health News:Prime Companies Revenue Stream Begins; Dentists in Every City and Town Available on Company's New Web Site 2
... MCS + 9000 system is Haemonetics' latest ... portfolio of protocols for the collection of ... these. It also offers a range of ... of this system enables blood collection organizations ...
... The PCS2 system ... for the collection of ... allow for the collection ... platelet-poor plasma, platelet-poor plasma ...
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
... Finnpipette Stepper, a lightweight, easy-to-use ... dispensing up to 45 times ... universal Stepper handle is adapted ... cover a dispensing volume range ...
Medicine Products: